Ozempic Cost: What Men Need to Know Before Starting Semaglutide

If you’ve looked into Ozempic recently, you already know the sticker shock is real. A single monthly supply of semaglutide — the active ingredient in both Ozempic and Wegovy — runs anywhere from $900 to $1,400 out of pocket in the United States, depending on the dose and pharmacy. That’s not a typo. And according to a landmark 2025 cost-effectiveness analysis published in JAMA Health Forum, semaglutide would need to be discounted by nearly semaglutide would require an 81.9% price discount from its current net price to reach the $100,000/QALY cost-effectiveness threshold just to reach the widely accepted $100,000 per quality-adjusted life-year (QALY) threshold — the standard benchmark insurers and health economists use to define value. In other words, by any rigorous economic measure, semaglutide at today’s prices is not considered cost-effective for most Americans. Understanding why that is — and what your real options are — matters whether you’re currently on a GLP-1 medication, considering one, or simply trying to make smart decisions about your metabolic health.

Why Ozempic Costs So Much and What the Research Actually Says

The high price of semaglutide is a function of patent protection, limited competition, and the enormous clinical infrastructure required to bring a drug like this to market. Novo Nordisk, which manufactures both Ozempic and Wegovy, has faced increasing scrutiny from lawmakers and economists over its pricing strategy — and the research backs up those concerns. The JAMA Health Forum analysis, which modeled lifetime outcomes for over 126 million eligible U.S. adults using data from the National Health and Nutrition Examination Survey, found that while semaglutide averted roughly 32,000 obesity cases per 100,000 individuals and reduced cardiovascular disease incidence meaningfully, its incremental cost-effectiveness ratio still came in at a staggering $467,676 per QALY — more than four times what most payers consider acceptable. Tirzepatide, the newer dual GIP/GLP-1 agonist sold as Mounjaro and Zepbound, performed better at $197,023 per QALY, but still fell short of cost-effectiveness thresholds at current pricing.

A separate 2023 analysis in Nutrition, Metabolism and Cardiovascular Diseases came to a similar conclusion, modeling five anti-obesity medications over a 40-year horizon and finding that tirzepatide’s incremental cost-effectiveness ratio reached $355,616 per QALY, while liraglutide and semaglutide were actually dominated — economically outperformed — by the older combination drug phentermine-topiramate, which is a fraction of the cost. A 2024 systematic review in the European Journal of Clinical Pharmacology reinforced this picture, concluding that while semaglutide does provide more QALYs than several alternatives, it may only become cost-effective with substantial price reductions and appears cost-effective primarily versus diet and exercise or liraglutide — not versus surgical options or lower-cost pharmacotherapy.

None of this means Ozempic doesn’t work. It clearly does. The clinical efficacy data is robust and the real-world evidence is growing. A comprehensive 2025 narrative review in Diabetes, Obesity and Metabolism confirmed that highly adherent patients on semaglutide and tirzepatide approach the weight loss outcomes seen in randomized controlled trials. But the same review flagged a serious practical problem: 20% to 50% of GLP-1 users discontinue within the first year, with high cost and side effects cited as the primary drivers. You can’t benefit from a medication you stop taking — and the economics of staying on it long-term are genuinely challenging for most men without comprehensive insurance coverage.

Insurance, Coverage Gaps, and Your Real-World Options

Insurance coverage for Ozempic and Wegovy is inconsistent at best. When prescribed for type 2 diabetes under the Ozempic label, many commercial insurance plans will cover it, often with a manageable copay — sometimes as low as $25 per month with the manufacturer’s savings card. But when prescribed for weight loss alone under the Wegovy label, coverage becomes far less reliable. Medicare Part D was historically prohibited from covering weight-loss drugs, though recent legislative changes are beginning to shift that landscape. Medicaid coverage varies dramatically by state. The result is that millions of men who would medically benefit from these medications simply can’t sustain them financially.

If you’re trying to figure out your options, a few practical paths exist. Manufacturer savings programs through Novo Nordisk can reduce monthly costs significantly for commercially insured patients, though they don’t help those on government programs. Compounding pharmacies have entered the market offering semaglutide at substantially lower prices — sometimes $150 to $300 per month — though the FDA has issued warnings about quality control and purity in compounded versions, and this space carries real risk if you’re not sourcing carefully. Generic versions of semaglutide are not yet available in the U.S., but the drug pipeline is expanding rapidly. A 2025 systematic review in Pharmacological Reviews identified dozens of emerging anti-obesity medications in phase 2 and phase 3 trials, including oral semaglutide formulations and next-generation incretin analogs, with the most promising results coming from the incretin analog class — suggesting that competition and innovation may eventually bring prices down. But that timeline is uncertain.

For men who can’t currently access or afford Ozempic, the honest answer is that structured lifestyle intervention still works. It is slower and requires more daily discipline, but the 2023 cost-effectiveness analysis makes this explicit: the combination of phentermine-topiramate, a significantly cheaper option, produced nearly identical QALYs to semaglutide at a fraction of the cost. Progressive resistance training, protein-forward nutrition, adequate sleep, and stress management are not glamorous, but they are the foundational tools that every man — whether on a GLP-1 or not — needs to be building around. If you are on Ozempic, those lifestyle pillars are what protect your muscle mass, keep weight off if you ever discontinue, and compound the medication’s benefits over time.

The Takeaway

Ozempic is a genuinely powerful tool for metabolic health — the science on that is not in dispute. But at current prices, the economics are broken for most men without the right insurance coverage, and the real-world data on discontinuation tells you that cost is already forcing people off these medications before they see full benefit. If you can access semaglutide affordably and sustainably, it may be worth discussing with your physician, particularly if you have obesity-related comorbidities. If you can’t, know that the gap between what these medications offer and what aggressive lifestyle optimization can deliver is smaller than the pharmaceutical marketing suggests — and the lifestyle work is something you’ll need to do regardless. Keep a close eye on pricing legislation and new entrants to the market. The landscape is shifting, and the economics of GLP-1 access are likely to look very different by the end of the decade.